Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
De Caterina R, Agnelli G, Laeis P, Unverdorben M, Rauer H, Wang CC, Nakamura M, Chiu KM, Reimitz PE, Koretsune Y, Chen C, Thee U, Kaburagi J, Kim YH, Choi WI, Yamashita T, Cohen A, Kirchhof P. De Caterina R, et al. Among authors: reimitz pe. Clin Cardiol. 2019 Dec;42(12):1147-1154. doi: 10.1002/clc.23279. Epub 2019 Oct 25. Clin Cardiol. 2019. PMID: 31650560 Free PMC article.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: reimitz pe. J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737. J Cardiovasc Med (Hagerstown). 2019. PMID: 30540648 Free article.
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: reimitz pe. BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x. BMC Cardiovasc Disord. 2019. PMID: 31299906 Free PMC article.
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P. de Groot JR, et al. Among authors: reimitz pe. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f30-f39. doi: 10.1093/ehjcvp/pvaa079. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32790837 Free PMC article.
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.
De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P; PREFER in AF Registry Investigators. De Caterina R, et al. Among authors: reimitz pe. Heart. 2014 Oct;100(20):1625-35. doi: 10.1136/heartjnl-2014-305486. Epub 2014 Aug 8. Heart. 2014. PMID: 25106421
Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry.
Brüggenjürgen B, Schliephacke T, Darius H, De Caterina R, Le Heuzey JY, Pittrow D, Reimitz PE, Schilling RJ, Zamorano JL, Kirchhof P. Brüggenjürgen B, et al. Among authors: reimitz pe. Value Health. 2014 Nov;17(7):A473. doi: 10.1016/j.jval.2014.08.1346. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201363 Free article. No abstract available.
Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry.
Brüggenjürgen B, Schliephacke T, Darius H, De CR, Le HJ, Reimitz PE, Schilling RJ, Schwertfeger M, Zamorano JL, Kirchhof P. Brüggenjürgen B, et al. Among authors: reimitz pe. Value Health. 2014 Nov;17(7):A497. doi: 10.1016/j.jval.2014.08.1484. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201497 Free article. No abstract available.
39 results